Marina Biotech gains $15M for work on RNAi, advancing familial adenomatous polyposis drug
This article was originally published in Scrip
Executive Summary
Marina Biotech, a developer of RNA interference drugs, will sell up to $15 million worth of equity over the next 30 months to Lincoln Park Capital Fund LLC, a Chicago-based institutional investor.